Cell line name |
HCT-116-MEK-R |
Accession |
CVCL_V401 |
Resource Identification Initiative |
To cite this cell line use: HCT-116-MEK-R (RRID:CVCL_V401) |
Comments |
Population: Caucasian. Selected for resistance to: ChEBI; CHEBI_88249; 391210-10-9 (PD0325901). Derived from site: In situ; Colon; UBERON=UBERON_0001155. |
Sequence variations |
- Mutation; HGNC; HGNC:173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line).
- Mutation; HGNC; HGNC:1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:9277; PPM1D; Simple; p.Leu450Ter (c.1349delT) (p.Leu450fs) (c.1344delT); Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line).
|
Disease |
Colon carcinoma (NCIt: C4910) |
Species of origin |
Homo sapiens (Human)
(NCBI Taxonomy: 9606) |
Hierarchy |
Parent: CVCL_0291 (HCT 116) |
Sex of cell |
Male |
Age at sampling |
48Y |
Category |
Cancer cell line |
Publications | PubMed=22402123; DOI=10.1158/1535-7163.MCT-11-1010 Hatzivassiliou G., Liu B., O'Brien C., Spoerke J.M., Hoeflich K.P., Haverty P.M., Soriano R.H., Forrest W.F., Heldens S., Chen H.-F., Toy K., Ha C., Zhou W., Song K., Friedman L.S., Amler L.C., Hampton G.M., Moffat J., Belvin M.P., Lackner M.R. ERK inhibition overcomes acquired resistance to MEK inhibitors. Mol. Cancer Ther. 11:1143-1154(2012) |
Cross-references |
Cell line databases/resources |
cancercelllines; CVCL_V401
|
Encyclopedic resources |
Wikidata; Q54882015
|
Polymorphism and mutation databases |
Cosmic; 1927247
|
Entry history |
Entry creation | 16-Apr-2014 |
Last entry update | 19-Dec-2024 |
Version number | 16 |
---|